4Ronaghi M,Uhlén M,Nyrén P. A sequencing method based on real-time pyrophosphate[J].Science,1998,(5375):363,365.
5Ronaghi M. Pyrosequencing sheds light on DNA sequencing[J].Genome Research,2001,(01):3-11.
6Kohlmann A,Klein HU,Weissmann S. The Interlaboratory RObustness of Next-generation sequencing (IRON) study:a deep sequencing investigation of TET2,CBL and KRAS mutations by an international consortium involving 10 laboratories[J].Leukemia:Official Journal of the Leukemia Society of America,Leukemia Research Fund,U.K,2011,(12):1840-1848.
7Karapetis CS,Khambata-Ford S,Jonker D J. K-ras mutations and benefit from cetuximab in advanced colorectal cancer[J].New England Journal of Medicine,2008,(17):1757-1765.
8Vaughn CP,Zobell SD,Furtado LV. Frequency of KRAS,BRAF,and NRAS mutations in colorectal cancer[J].Genes,Chromosomes and Cancer,2011,(05):307-312.
9Ogino S,Meyerhardt JA,Irahara N. KRAS mutation in stage Ⅲ colon cancer and clinical outcome following intergroup trial CALGB 89803[J].Clinical Cancer Research,2009,(23):7322-7329.
10Richman SD,Seymour MT,Chambers P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan:results from the MRC FOCUS trial[J].Journal of Clinical Oncology,2009,(35):5931-5937.doi:10.1200/JCO.2009.22.4295.
